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A B S T R A C T
The aryl hydrocarbon receptor (AHR) controls interleukin 22 production by T helper 17 cells (Th17). IL-22
contributes to intestinal homeostasis but has also been implicated in chronic inﬂammatory disorders and col-
orectal cancer, highlighting the need for appropriate regulation of IL-22 production. Upon activation, the AHR
induces expression of cytochrome P4501 (CYP1) enzymes which in turn play an important feedback role that
curtails the duration of AHR signaling by metabolizing AHR ligands. Recently we described how agents that
inhibit CYP1 function potentiate AHR signaling by disrupting metabolic clearance of the endogenous ligand 6-
formylindolo[3,2-b]carbazole (FICZ). In the present study, we investigated the immune-modulating eﬀects of
environmental pollutants such as polycyclic aromatic hydrocarbons on Th17 diﬀerentiation and IL-22 produc-
tion. Using Th17 cells deﬁcient in CYP1 enzymes (Cyp1a1/1a2/1b1−/−) we show that these chemicals po-
tentiate AHR activation through inhibition of CYP1 enzymes which leads to increases in intracellular AHR
agonists. Our ﬁndings demonstrate that IL-22 production by Th17 cells is profoundly enhanced by impaired
CYP1-function and strongly suggest that chemicals able to modify CYP1 function or expression may disrupt AHR-
mediated immune regulation by altering the levels of endogenous AHR agonist(s).
1. Introduction
The aryl hydrocarbon receptor (AHR) has emerged as a critical
physiological regulator of immunity and has been implicated in the
development of chronic inﬂammatory diseases such as inﬂammatory
bowel disease and colorectal cancer [1,2]. The AHR is a ligand-de-
pendent transcription factor renowned for mediating the toxic eﬀects of
halogenated aromatic hydrocarbons such as dioxins. Upon activation
AHR regulates the expression of numerous target genes including those
encoding the cytochrome P4501 (CYP1) biotransforming enzymes [3],
that are also involved in control of AHR activity [4]. This negative
feedback regulation is of functional signiﬁcance as sustained AHR ac-
tivation, exempliﬁed by the non-metabolized AHR ligand 2,3,7,8-tet-
rachlorodibenzo-p-dioxin (TCDD), has detrimental eﬀects resulting in
immunotoxicity, teratogenicity and endocrine disruption [5].
The endogenous AHR ligand 6-formylindolo[3,2-b]carbazole (FICZ)
has the highest AHR activating potency among identiﬁed endogenous
agonists [6,7]. FICZ is also eﬃciently metabolized by the AHR-regu-
lated CYP1 enzymes, resulting in transient AHR pathway activation [8].
In a number of reports we have described how CYP1 knockdown or
chemicals inhibiting the CYP1 function such as α-naphthoﬂavone
(αNF) and 3′methoxy-4′nitroﬂavone (MNF) disrupt this negative feed-
back loop and prolong AHR activity in vitro and in vivo [8–12]. Fur-
thermore, adverse eﬀects such as immunosuppression [13] and sy-
nergistic developmental toxicity have been observed after exposure to
an AHR inducer such as β-naphthoﬂavone, benzo(a)pyrene or FICZ in
combination with deletion of the Cyp1a1 gene or with chemical CYP1
inhibition [14–17]. Altogether, these reports strengthen an important
role of CYP1 enzymes in regulation of AHR physiological functions in
embryo development and immunity.
The AHR is highly expressed in T helper 17 cells (Th17) and its role
in Th17 cell function has been studied extensively [18]. Th17 cells are
particularly enriched in the gastrointestinal tract and AHR pathway
activation is important for the production of the cytokine IL-22 by Th17
cells. IL-22 promotes epithelial barrier integrity by inducing production
of anti-microbial proteins and mucins from epithelial cells, which is
crucial for protective immunity to extracellular pathogens such as Ci-
trobacter rodentium but also limits the dissemination of commensal
https://doi.org/10.1016/j.bcp.2018.02.031
Received 7 January 2018; Accepted 23 February 2018
⁎ Corresponding author at: Swetox, Karolinska Institutet, Unit of Toxicology Sciences, Forskargatan 20, 151 36 Södertälje, Sweden.
E-mail addresses: chris.schiering@crick.ac.uk (C. Schiering), anne.vonk@student.hu.nl (A. Vonk), srustidhar.das@ki.se (S. Das), brigitta.stockinger@crick.ac.uk (B. Stockinger),
emma.wincent@swetox.se (E. Wincent).
Biochemical Pharmacology 151 (2018) 47–58
Available online 01 March 2018
0006-2952/ © 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
bacteria to peripheral organs [19,20]. In contrast, IL-22 has been shown
to contribute to immune-mediated pathology by promoting the secre-
tion of pro-inﬂammatory chemokines and cytokines [20]. In addition,
IL-22 signaling is involved in the development of colorectal cancer by
increasing the proliferation and survival of intestinal stem cells [19].
These complex roles of IL-22 in the context of intestinal homeostasis,
immunity and tumorigenesis emphasize the importance of appropriate
regulation of IL-22 production.
Based on our previous work demonstrating a crucial role of CYP1
enzymes in AHR signaling [10–12] and downstream regulation of im-
munity [9], we hypothesized that chemicals interfering with the feed-
back regulation of AHR activity modulate IL-22 by causing prolonged
and potentiated AHR signaling. To this aim, we compared the impact of
diﬀerent CYP1 inhibiting chemicals on AHR signaling and IL-22 pro-
duction in in vitro diﬀerentiated Th17 cells generated from wildtype
(WT), Cyp1a1/1a2/1b1 triple knockout (CYP1-KO) or Ahr knockout
(AHR-KO) mice. Th17 cells generated from these genotypes were ex-
posed to the AHR ligand FICZ with or without co-exposure to CYP1
inhibitors. Subsequently, eﬀects on AHR activation, Th17 cell diﬀer-
entiation, IL-22 expression and CYP1 enzymatic function were de-
termined by ﬂow cytometry, analyses of gene and protein expression
and FICZ metabolism studies.
2. Materials and methods
2.1. Mice
Cyp1a1/1a2/1b1 triple knockout (CYP1-KO) and Ahr knockout
(AHR-KO) mice used in this study were backcrossed to C57BL/6 mice
for at least 10 generations. Wild type C57BL/6J mice were used as
control. All mice were bred in the Francis Crick Institute animal facility
under speciﬁed pathogen-free conditions. All animal procedures were
conducted under a Project Licence granted by the UK Home Oﬃce.
Mice were age- and sex-matched and between 6 and 10weeks old when
ﬁrst used. Both female and male mice were used in experiments.
Exclusion criteria such as inadequate staining or low cell yield owing to
technical problems were pre-determined.
2.2. Th17 cell diﬀerentiation and chemical exposure
CD4+T cells were isolated from peripheral lymph nodes of C57BL/
6 mice using EasySep mouse CD4+T cell isolation kit (Stemcell
Technologies, Cambridge, UK) with the addition of biotinylated anti-
CD25 antibody (BioLegend, London, UK). The cells were suspended in
IMDM medium containing 2mM L-glutamine, 100 U/ml penicillin,
100 µg/ml streptomycin, 0.05mM β-mercaptoethanol and 5% fetal calf
serum (Biosera Europe, Nuaille, France) and dispensed on 48-well
plates (0.2× 106 cells/500 μl medium per well) pre-coated with 1 µg/
ml anti-CD3 (clone 145-2C11, eBioscience, San Diego, USA) and 10 µg/
ml soluble anti-CD28 (clone 37.51, BioLegend, London, UK). To sti-
mulate polarization towards Th17 lineage, the cells were cultured in the
presence of 2 ng/ml TGF-β1, 20 ng/ml IL-6, 10 ng/ml IL-1β (all R&D
Systems) and 10 μg anti-IFN-γ (BioXCell, West Lebanon, USA). All cy-
tokine stimulation and chemical exposures were started within 30min
after plating the cells by adding an additional 500 μl of IMDM medium
containing 2× cytokine concentrations and 2× concentrations of FICZ,
indolo[3,2-b]carbazlole (ICZ) (both from Syntastic, Stockholm,
Sweden) or TCDD (LGC standards, Boras, Sweden) and/or the CYP1
inhibitors MNF (kind gift from Michael S. Denison, University of
California, Davis, CA), α-NF, ﬂuoranthene (FL), phenanthrene (Phe) or
pyrene (PY) (all from Sigma-Aldrich, Stockholm, Sweden), thereby
achieving 1× concentration of respective chemical (0.01 nM–5 μM)
and cytokine. All chemicals were dissolved and diluted in DMSO which
therefore was included as vehicle control in all exposures (0.1%). At
diﬀerent time points cells were harvested for FACS analysis, gene ex-
pression analysis or HPLC analysis. In parallel, IL-22 cytokine levels in
culture supernatants were determined by ELISA (eBioscience, San
Diego, USA).
2.3. Intracellular cytokine staining and ﬂow cytometry
At 4 days post exposure the cells were re-stimulated in the culture
medium for 4 h in the presence of 0.1 μg/ml phorbol-12-myristate-13-
acetate (PMA), 1 μg/ml ionomycin, 1 μg/ml monensin and 1 μg/ml
brefeldin A (all from Sigma-Aldrich, Gillingham, UK). Thereafter, the
cells were washed and cell suspensions were incubated with anti-CD16/
CD32 (eBioscience, San Diego, USA) and ﬁxable live/dead cell dye
(ThermoFisher, Waltham, USA) followed by staining with antibody
against the surface marker CD4 (BD Biosciences, Oxford, UK). For in-
tracellular staining, the cells were then ﬁxed in 3.7% formaldehyde in
DPBS on ice for 45min, followed by permeabilization in permeabili-
zation buﬀer (eBioscience, San Diego, USA) for 45min on ice. The cells
were pelleted and resuspended in fresh permeabilization buﬀer con-
taining antibodies against IL-17A, IL-22, IFNɣ and FoxP3 (all
eBioscience, San Diego, USA). Cells were acquired with a BD Fortessa
X20 and analysis was performed on viable cells with FlowJo v10 soft-
ware (Tree Star, Ashland, USA).
2.4. RNA puriﬁcation and gene expression analysis
At diﬀerent time points, cells were harvested and total RNA was
extracted using the RNeasy plus extraction kit (Qiagen, Sollentuna,
Sweden) and cDNA was synthesized using the iScript cDNA Synthesis
kit (Biorad, Solna, Sweden), both according to the manufacturer’s in-
structions. Expression of Hprt, Ahr, Cyp1a1 and Il22 was determined by
means of quantitative real-time PCR (qRT-PCR) using TaqMan® Gene
Table 1
TaqMan® Gene Expression Assay IDs.
Gene Assay ID
hypoxanthine guanine phosphoribosyl transferase (Hprt) Mm03024075_m1
aryl hydrocarbon receptor (Ahr) Mm00478932_m1
cytochrome p4501a1(Cyp1a1) Mm00487218_m1
interleukin 22 (Il22) Mm01226722_g1
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Fig. 1. Time- and dose dependent AHR activation by FICZ. Dose dependent eﬀects of FICZ
on Cyp1a1 expression in CD4+T cells undergoing Th17 diﬀerentiation was determined
up to 72 h exposure. Results are shown as mean ± SD from 2 independent experiments
each performed in duplicate (n= 4). Relative levels of Cyp1a1 transcription was calcu-
lated using Hprt as a reference gene and untreated cells at each time-point as controls.
Diﬀerences in transcription between DMSO control and respective FICZ-dose were de-
termined using One-way ANOVA followed by Sidak post hoc test to correlate for multiple
comparisons. Statistically signiﬁcant diﬀerences are shown by asterisks (∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.001. n.s. = not signiﬁcant).
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Expression Assay probes (Applied biosystems, Foster City, USA), with
detection on an Applied Biosystems 7500 Real-Time PCR system. Gene
expression quantiﬁcation was based on the comparative threshold cycle
method (2−ΔΔCt) where level of expression for respective gene was
normalized to Hprt and given relative to untreated WT cells or WT cells
exposed to negative control (DMSO) at each time point. qRT-PCR
analysis was performed with the following protocol: 95 °C for 10min,
followed by 35–45 cycles of 95 °C for 15 s and 60 °C for 60 s. Gene
expression assay IDs are given in Table 1.
2.5. HPLC analysis
CD4+T cells were cultured under Th17-cell polarizing conditions
and exposed as described above. At various time-points cells were
collected, washed, extracted and analyzed as previously described
[9,10]. In brief, cells were washed in PBS, re-suspended in distilled
water, homogenized by sonication on ice, extracted in acetonitrile and
analyzed by means of HPLC using an in-line solid-phase extraction
column coupled to a reverse-phase C18 analytical column. FICZ quan-
tity was determined according to a standard curve of FICZ prepared in
same matrix as the analyzed samples and normalized to total protein
contents determined by PierceTM Coomassie (Bradford) protein assay
kit (ThermoFisher, Gothenburg, Sweden) according to the manu-
factureŕs instructions.
2.6. Statistical analysis
All statistical analysis was calculated in Prism 6 (GraphPad Software
Inc., La Jolla, USA). The statistical methods used to determine eﬀects on
mRNA expression and IL-22 protein levels were one-way ANOVA fol-
lowed by Sidak post hoc tests or by two-way ANOVA followed by Holm-
Sidak post hoc test. Statistical signiﬁcance of more than additive eﬀects
was determined using Student’s t test followed by Holm–Sidak post hoc
test. For this analysis, calculated levels of gene- or protein expression,
i.e. the sum of the single exposures (FICZ, TCDD or ICZ alone+CYP1
inhibitor alone), was compared to the observed levels of expression
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Fig. 2. Role of CYP1 function in Th17 diﬀerentiation and IL-22 expression. CD4+T cells isolated from WT mice (A-top panel, B) or CYP1-KO mice (A-bottom panel, C) undergoing Th17
diﬀerentiation were exposed to diﬀerent doses of FICZ. At 96 h exposure frequency of CD4+T cells expressing IL17A and IL-22 was determined by means of FACS and at 72 h exposure
cell medium was collected and analysed for content of IL-22 by ELISA. All results are shown as mean ± SD from 2 independent experiments each performed in duplicate (n= 4). All
statistical diﬀerences were determined using One-way ANOVA followed by Sidak post hoc test to correlate for multiple comparisons. Statistically signiﬁcant diﬀerences between DMSO
control and respective FICZ-dose in WT cells (B) or CYP1-KO cells (C) are shown by asterisks (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Statistically signiﬁcant diﬀerences between WT
cells (B) and CYP1-KO cells (C) for respective exposure are shown by hashtags (#p < 0.05).
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after co-exposure to FICZ, TCDD or ICZ+CYP1 inhibitor. The statis-
tical tests used are given in the ﬁgure legends together with the number
of experiments and experimental repeats included in the statistical
analysis.
3. Results
3.1. Dose- and time-dependent kinetics of FICZ mediated AHR activation,
Th17 cell diﬀerentiation and IL-22 expression
To investigate the kinetics of AHR activation in Th17 cells, Cyp1a1
expression was determined over time in CD4+ T cells undergoing Th17
cell diﬀerentiation while at the same time being exposed to a wide
range of FICZ doses (0.01–100 nM).
3.1.1. FICZ-mediated AHR activation during Th17 cell diﬀerentiation
A signiﬁcant induction of AHR signaling, measured as Cyp1a1 ex-
pression, was observed at 0.01 nM FICZ, with maximum induction at
24 h (Fig. 1). A clear dose-dependent diﬀerence was observed wherein
exposure to 0.01–1.0 nM FICZ displayed a transient induction of Cyp1a1
expression peaking at 24 to 48 h exposure, while in cells exposed to
10–100 nM FICZ expression levels of Cyp1a1 were still increasing at
72 h. At 24 h of exposure, a non-linear dose-response was observed
where exposure to 100 nM FICZ resulted in lower Cyp1a1 expression
levels as compared to 0.1 nM.
3.1.2. Role of CYP1 function in FICZ-mediated Th17 cell diﬀerentiation
and IL-22 production
The role of CYP1 enzymes in modulating intracellular levels of FICZ
[9,10,21], together with the observed dose-response relationship in
FICZ-induced Cyp1a1 expression (Fig. 1), prompted us to investigate
the impact of impaired CYP1 expression on Th17 diﬀerentiation. To this
end we compared Th17 cell diﬀerentiation in WT and CYP1-KO CD4+ T
cells exposed to 0.01–100 nM FICZ from the start of culture. As ex-
pected [9], addition of FICZ to WT CD4+ T cells enhanced Th17 cell
diﬀerentiation and IL-22 expression (Fig. 2A and B). Comparison of
IL17A+IL-22− and IL-17A+IL-22+ cells revealed that IL-22 expression
was more strongly induced by FICZ and at lower concentrations com-
pared to IL-17A expression. In accordance with our previous results [9]
CYP1-KO CD4+ T cells displayed signiﬁcantly enhanced Th17 cell
diﬀerentiation and IL-22 expression compared to WT cells even in the
absence of exogenous FICZ (i.e. DMSO control, Fig. 2A–C). Further
exposure of CYP1-KO CD4+ T cells to FICZ generated an inverted u-
shaped dose-response curve characterized by maximal induction of
Th17 cell diﬀerentiation and IL-22 production observed at 0.1 nM FICZ
exposure followed by a decline at higher concentrations (Fig. 2C). At
100 nM FICZ, WT cells and CYP1-KO cells show the same response for
all endpoints. The diﬀerence in dose-response pattern observed with
CYP1-KO cells compared to WT cells suggests that the Th17/IL-22 re-
sponse in CYP1-KO CD4+ T cells is saturated or even reduced at FICZ
levels above 10 nM, while WT CD4+ T cells are not. In addition, the
CYP1-KO cells showed a signiﬁcantly stronger response to FICZ com-
pared to WT cells, both in Th17 diﬀerentiation (0.01–1.0 nM) and IL-22
expression (0.01–10 nM FICZ).
Similar results were observed for Il22mRNA expression (Fig. 3). The
Il-22 expression data reveal diﬀerences in dose- and time-response
trends with WT cells compared to CYP1-KO. WT cells showed transient
induction up to 1 nM FICZ and continuous increase in expression at
10–100 nM while CYP1-KO cells showed a continuous increase over
time, at all doses. CYP1-KO cells lacked dose dependent IL-22 induction
by FICZ. Only the lower doses of FICZ produced signiﬁcantly higher
levels of IL-22 than the DMSO control (Fig. 3B). Also, CYP1-KO cells
showed same response as WT cells at 10 nM and even lower response at
100 nM FICZ, further strengthening a saturated response in absence of a
functional CYP1.
3.2. Impact of chemical CYP1-inhibitors on AHR activation and IL-22
expression during Th17 cell diﬀerentiation
Exposure to diﬀerent types of CYP1 inhibiting chemicals and agents
has been shown to enhance and/or prolong FICZ-mediated AHR sig-
naling in various human cells and in zebraﬁsh embryos
[8,10–12,22,23]. Similar AHR potentiation has been observed after co-
exposure to polycyclic aromatic hydrocarbon (PAH)-type AHR activa-
tors such as benzo(a)pyrene and β-naphthoﬂavone and CYP1 inhibitors
[14,15,24,25]. Thus, we next set out to determine whether chemical
CYP1 inhibitors potentiate AHR signaling during Th17 cell diﬀer-
entiation.
3.2.1. Eﬀects of model CYP1 inhibitors on FICZ-mediated AHR signaling
and Il22 gene expression
At ﬁrst, eﬀects of the previously described potent CYP1 inhibiting
chemicals 3′methoxy-4′nitroﬂavone (MNF) and α-naphthoﬂavone
(αNF) were determined. Expression levels of Cyp1a1 and Il22 were
determined in WT cells exposed to FICZ (0.1 nM) alone or in combi-
nation with MNF (0.05–0.5 μM) or αNF (0.01–0.5 μM). Both these
compounds have previously been shown to activate AHR signaling by
reducing the CYP1-dependent cellular clearance of FICZ and to strongly
potentiate FICZ-dependent AHR activation [8,10,11]. The FICZ-dose
was selected based on the low and transient eﬀect on AHR signaling
observed with this dose in WT cells (Fig. 1), allowing for both a po-
tentiated and prolonged AHR response. The cutoﬀ at 0.5 μM as highest
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Fig. 3. Impact of CYP1 knockout on FICZ-mediated Il22 expression over time. WT or
CYP1-KO CD4+T cells undergoing Th17 diﬀerentiation were sampled at 24, 48 and 72 h
exposure and expression of Il22 was determined by means of qRT-PCR. (A) Comparison of
time-trends in Il22 expression with WT (black triangle) and CYP1-KO (grey circle) cells at
exposure to DMSO control or diﬀerent doses of FICZ. (B) Comparison of dose-responses in
WT cells and CYP1-KO cells separately. Level of expression is normalized to Hprt and
given relative to untreated WT cells at each time point. All results are shown as
mean ± SD from 2 independent experiments each performed in duplicate (n= 4).
Diﬀerences in Il22 expression between WT and CYP1-KO cells for respective exposure
were determined using One-way ANOVA followed by Sidak post hoc test to correlate for
multiple comparisons. Statistically signiﬁcant diﬀerences are shown by asterisks
(∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001).
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dose of MNF and αNF was based on reduced viability observed at
higher doses (data not shown).
FICZ alone caused induced expression of Cyp1a1 and Il22, with a
more transient appearance for Cyp1a1 compared to Il22 (Fig. 4A–D).
MNF alone did not induce expression of either gene, but rather showed
a tendency towards reduced expression compared to DMSO control and
an antagonistic eﬀect at co-exposure to FICZ at the highest MNF dose
(Fig. 4A and B). At the lower doses of MNF however, co-exposure with
FICZ resulted in more than additive induction of gene expression
(Fig. 4A and B). These synergistic eﬀects were dependent on both dose
and time and diﬀered in kinetics for Cyp1a1 and Il22. In general, eﬀects
on Cyp1a1 expression appeared earlier and were of more transient
nature compared to Il22. At 48 h exposure, synergistic Cyp1a1 expres-
sion was observed in a reversed dose-response manner, while at 72 h
and 96 h co-exposure only 0.1 μM MNF caused synergistic induction.
For Il22 expression, synergistic inductions were observed at 72 h and
96 h co-exposure, with a time-dependent increase in expression levels.
In contrast to MNF, αNF alone generated an increase in expression of
both Cyp1a1 and Il22 (Fig. 4C and D) and synergistic inductions were
observed at 48 h and 72 h co-exposure to FICZ with all doses of αNF. At
96 h co-exposure, Cyp1a1 expression levels were reduced and sy-
nergistic induction was observed only with 0.05 μM αNF, while Il22
expression levels were almost three times higher compared to 72 h co-
exposure.
3.2.2. Functional eﬀects of MNF and αNF on Th17 cell diﬀerentiation and
IL-22
To determine functional eﬀects of chemically induced AHR po-
tentiation, the level of Th17 cell diﬀerentiation and IL-22 expression
was determined in WT and AHR-KO cells after 96 h exposure to FICZ
+/− MNF or αNF. Similar to eﬀects observed at the gene expression
level, exposure to MNF alone showed a suppressive tendency compared
to DMSO control at the level of Th17 cell diﬀerentiation and IL-22
expression (Fig. 5A). However, levels of IL-22 in cell medium did not
diﬀer from DMSO control (Fig. 5B). In co-exposure with FICZ, a re-
versed dose-response was observed for fraction of IL17A+IL-22+ cells
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Fig. 4. Eﬀects of model CYP1 inhibitors on
FICZ-mediated AHR activation and Il22 ex-
pression. CD4+T cells (WT) undergoing
Th17 diﬀerentiation were exposed to dif-
ferent doses of the model CYP1 inhibitors
MNF (A-B) or αNF (C-D), with or without co-
exposure to 0.1 nM FICZ (abbreviated; F). At
48, 72 and 96 h exposure cells were harvested
and expression of Cyp1a1 and Il22 was de-
termined. All results are shown as
mean ± SD from 2 independent experiments
each performed in duplicate (n=4). Level of
expression is normalized to Hprt and given
relative to DMSO control (abbreviated; D) at
each time point. Analysis of statistical diﬀer-
ences between each exposure compared to
the DMSO control at respective time-point
was performed using two-way ANOVA fol-
lowed by Sidaḱs post hoc test to correlate for
multiple comparisons. Studentś t test fol-
lowed by Holm-Sidak post hoc test was used
for statistical analysis of more or less than
additive eﬀects. Asterisks indicate statistically
signiﬁcant diﬀerences between DMSO control
and respective exposure (∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.001). Daggers
designate signiﬁcantly more or less than ad-
ditive eﬀects in co-exposures compared to
sum of single exposures (†p < 0.05).
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and IL-22 expression (Fig. 5A-B) where the two lower doses of MNF
caused a synergistic induction of IL-22 levels in cell medium and the
highest dose generated an antagonistic eﬀect (Fig. 5B). No increase in
fraction of IL17A+IL-22− cells was however observed.
Eﬀects of αNF alone or in co-exposure with FICZ (Fig. 5C-D) also
very much resembled the eﬀects at the gene expression level, with dose-
dependent induction of IL-22 expression by αNF alone and synergistic
induction at co-exposure to FICZ. A tendency toward increased Th17
cell diﬀerentiation was also observed.
To conﬁrm the role of AHR in these eﬀects, CD4+T cells isolated
from AHR-KO mice were exposed to FICZ +/− MNF or αNF and
analyzed for level of Th17 diﬀerentiation and IL-22 expression. As seen
in Fig. 5E-F, deletion of Ahr strongly reduced the fraction of IL17A+IL-
22− cells and completely abolished the expression of IL-22, in-
dependent of chemical exposure.
3.2.3. Impact of environmentally relevant CYP1 inhibitors on AHR
signaling, Th17 cell diﬀerentiation and IL-22
The vast number of pharmaceutical drugs, dietary compounds,
metals and environmental chemicals known to impair the function of
CYP1 enzymes [10,26–29] suggest this may indeed be an overlooked
mechanism of dysregulated IL-22 signaling. To further test this hy-
pothesis we repeated the experimental setup using the environmentally
relevant PAHs ﬂuoranthene (FL), pyrene (PY) and phenanterne (Phe),
all known to inhibit CYP1 function [30]. As in the previous experi-
ments, CD4+T cells were exposed to FICZ +/− CYP1 inhibitor from
start of Th17 polarization and samples for analysis of gene expression,
cell diﬀerentiation and IL-22 expression were taken at 72 h and 96 h
exposure, respectively. To cover a wide dose range of the PAHs, three
doses diﬀering with a factor of 10 were selected (0.05, 0.5 and 5.0 μM)
with the two lowest doses in range of concentrations measured in
human blood [31–34].
Regarding AHR activation, none of the three PAHs alone evoked
signiﬁcant induction of Cyp1a1 expression at 72 h exposure, while they
all generated synergistic induction in combination with 0.1 nM FICZ
(Fig. 6A), PY showing the strongest and Phe the weakest potentiation.
From a dose-response perspective, Phe diﬀered compared to FL and PY
by showing a trend for a dose-dependent increase in potentiation while
Fig. 5. Impact of MNF and αNF on FICZ-mediated Th17 cell diﬀerentiation and IL-22 expression. CD4+T cells (WT) undergoing Th17 diﬀerentiation were harvested at 96 h exposure to
diﬀerent doses of MNF (A-B) or αNF (C-D) with or without co-exposure to 0.1 nM FICZ (abbreviated; F). The frequency of CD4+T cells expressing IL17A alone (IL17A(+), IL-22(-)) or
together with IL-22 (IL17A(+), IL-22(+)) was determined by means of FACS. In parallel, cell medium was harvested and analysed for levels of IL-22 by means of ELISA (B, D). Similar
exposures and analysis were performed using CD4+T cells isolated from Ahr−/− mice (E-F). All FACS analysis were performed on pooled duplicates from one experiment while ELISA
results are shown as mean ± SD from 2 independent experiments each performed in duplicate or triplicate (n= 4–6). Analysis of statistical diﬀerences in IL-22 expression between each
exposure compared to the DMSO control was performed using one-way ANOVA followed by Sidaḱs post hoc test to correlate for multiple comparisons. Studentś t test followed by Holm-
Sidak post hoc test was used for statistical analysis of more or less than additive eﬀects. Asterisks indicate statistically signiﬁcant diﬀerences between DMSO control and respective
exposure (∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001). Daggers designate signiﬁcantly more or less than additive eﬀects in co-exposures compared to sum of single exposures
(†p < 0.05).
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the latter two showed a clear reversed dose-response. Similar results
were observed with Il22 expression (Fig. 6B). Here, no induction was
observed after exposure to the PAHs alone or to FICZ alone, while
diﬀerent levels of synergy was observed at co-exposure to each separate
PAH+FICZ. Unlike the dose-response of Cyp1a1 expression all three
PAHs generated a reverse dose-response trend for the potentiation of
Il22. Again, PY showed strongest potentiation of expression, followed
by FL and Phe.
Regarding functional eﬀects, some of the PAHs showed a tendency
to induce Th17 cell diﬀerentiation and IL-22 expression at the lower
concentrations and to reduce Th17 diﬀerentiation at the highest con-
centration (Fig. 7). At co-exposure to FICZ, all three PAHs generated
synergistic induction of IL-22 expression in a reversed dose-response
manner (Fig. 7B, D, F). AHR-KO cells were used to conﬁrm the role of
AHR in eﬀects of FL, PY and Phe on Th17 diﬀerentiation and IL-22
expression (Fig. 7G). As with MNF and αNF, fraction of Th17 cells were
strongly reduced, independent of exposure, and IL-22 expression was
close to abolished.
3.2.4. Impact of CYP1 inhibitors on AHR signaling and Il22 gene expression
induced by TCDD or ICZ
To further investigate the impact of CYP1 inhibition on AHR sig-
naling and Il22 gene expression we next compared the eﬀect of MNF
and PY on AHR activation mediated by TCDD and indolo[3,2-b]car-
bazole (ICZ). TCDD is a potent AHR ligand known to be poorly meta-
bolized by CYP1 enzymes while ICZ, a derivative of the dietary com-
ponent indole-3-carbinol, represents an AHR ligand readily metabolized
by CYP1 enzymes [21,35,36]. CD4+T cells were exposed to TCDD or
ICZ +/− MNF or PY from the start of Th17 polarization and samples
for analysis of gene expression were taken at 48 h, 72 h and 96 h ex-
posure (Fig. 8). Due to diﬀerences in AHR potency, TCDD was used at
0.1 nM while ICZ was used at 1 nM. The dose for MNF and PY (0.05 µM)
were based on previous experiments. Exposure to TCDD generated a
sustained induction of both Cyp1a1 (Fig. 8A) and Il-22 (Fig. 8B), with
expression levels still increasing at 96 h exposure. In contrast, ICZ
showed maximum induction at 72 h exposure, followed by a reduced
induction at 96 h. Similar to our observations with FICZ, co-exposure of
Th17 cells to ICZ and MNF or PY led to synergistic induction of Cyp1a1
and Il22 expression. By contrast, co-exposure of TCDD and MNF or PY
inhibited AHR-mediated gene expression in Th17 cells. Although we
currently do not understand the mechanisms by which MNF or PY ab-
rogate TCDD potency our data strongly suggest that CYP1 inhibition by
PY and MNF potentiates signaling only in response to metabolizable
AHR ligands.
3.3. Chemical CYP1 inhibition as a mechanism of induced IL-22 expression
and reduced FICZ metabolism in Th17 cells
Although the selected chemicals are known inhibitors of CYP1
function, we next wanted to conﬁrm the impact of their innate in-
hibitory function on IL-22 production. In theory, if CYP1 inhibition is
the mechanism underlying their capacity to potentiate FICZ-mediated
induction of IL-22 expression, two qualities need to be fulﬁlled; i) they
should not be able to induce IL-22 expression in a Cyp1-depleted
system, and ii) they should reduce cellular clearance of FICZ.
3.3.1. Impact of chemical CYP1 inhibitors on IL-22 production in CYP1-
knockout cells
As shown in the previous experiments, exposure to several of the
CYP1-inhibitors alone generated induced expression of Il22 and/or le-
vels of IL-22 excreted in cell medium. To investigate whether these
inductions are due to impaired CYP1 function, we next compared ef-
fects of MNF, αNF, FL, PY or Phe alone on IL-22 in WT cells with eﬀects
in CYP1-KO cells. Here, exposure to FICZ or αNF induced Il22 expres-
sion (Fig. 9A), while all exposures except MNF and PY caused induced
levels of IL-22 excretion in WT cells (Fig. 9B). Exposure to MNF showed
antagonistic eﬀects at both gene- and protein expression levels. No-
tably, responses in CYP1-KO cells diﬀered completely (Fig. 9C and D).
In these cells, only FICZ was able to induce gene- and protein expression
of IL-22 (compared to DMSO) and the potent induction by αNF alone
observed in WT cells was reversed into a signiﬁcant antagonistic re-
sponse. MNF showed antagonistic eﬀects similar to WT cells while all
three PAHs showed no eﬀects compared to DMSO control.
3.3.2. Impact of chemical CYP1 inhibitors on FICZ metabolism in Th17
cells
Our previous studies have shown a clear link between MNF- and
αNF-mediated CYP1 inhibition and reduced cellular clearance of FICZ,
with potentiation of AHR signaling as consequence [8,10,11]. To in-
vestigate whether the CYP1 inhibitors used in this study act in the same
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Fig. 6. Impact of PAH-type CYP1 inhibitors on
FICZ-mediated AHR activation and Il22 expres-
sion. CD4+T cells (WT) undergoing Th17 dif-
ferentiation were exposed to diﬀerent doses of the
PAHs ﬂuoranthene (FL), pyrene (PY) or phe-
nanterne (Phe) with or without co-exposure to
0.1 nM FICZ (abbreviated; F). At 72 h exposure,
cells were harvested and the expression of Cyp1a1
(A) and Il22 (B) was determined. All results are
shown as mean ± SD from 2 independent ex-
periments performed in duplicate and triplicate,
respectively (n= 5). Level of expression is nor-
malized to Hprt and given relative to DMSO con-
trol (abbreviated; D). Signiﬁcant diﬀerences be-
tween DMSO control and respective exposure
were determined using One-way ANOVA followed
by Sidak post hoc test to correlate for multiple
comparisons. Studentś t test followed by Holm-
Sidak post hoc test was used for statistical analysis
of more or less than additive eﬀects. Asterisks
indicate statistically signiﬁcant diﬀerences be-
tween DMSO control and respective exposure
(∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001).
Daggers designate signiﬁcantly more or less than
additive eﬀects in co-exposures compared to sum
of single exposures (†p < 0.05).
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manner during Th17 cell diﬀerentiation, cellular levels of FICZ were
determined after co-exposure to diﬀerent doses of CYP1 inhibitors
(Fig. 10). Cellular uptake of FICZ was observed already at the ﬁrst
sampling point (1h exposure) and reached maximum levels at 5 h, after
which levels had slightly declined at 8 h followed by strongly reduced
levels at 24 h and only low levels remaining at 48 h. Co-exposure to
αNF or MNF showed comparable eﬀects on FICZ clearance. Both
compounds caused signiﬁcantly higher cellular levels of FICZ at 8–48 h
in a dose-dependent manner (Fig. 10A and B), the higher dose showing
stronger and more sustained eﬀects for both compounds.
Similar trends were observed at co-exposure to FL and PY. Here, co-
exposure to FL caused increased levels of FICZ at 24 h, while PY caused
increased levels at both 8 h and 24 h (Fig. 10C and D). As with MNF and
αNF, the higher doses were more eﬃcient in reducing cellular clearance
IL 1 7 A (+ ) , IL -2 2 (- )
%
o
f
liv
e
C
D
4
+
T
ce
lls
D
F
0 .
1 n
M
F L
0 .
5
M
P h
e
0 .
5
M
P Y
0 .
5
M F L P Y P h
e
0
2 0
4 0
6 0
8 0
+FICZ
IL 1 7 A (+ ) , IL -2 2 (- )
%
o
f
liv
e
C
D
4
+
T
ce
lls
D
F
0 .
1 n
M
0 .
0 5 0 .
5 1 0
0 .
0 5 0 .
5 1 0
0
2 0
4 0
6 0
8 0
F L [ M] F L [ M]
+FICZ
IL 1 7 A (+ ) , IL -2 2 (+ )
%
o
f
liv
e
C
D
4
+
T
ce
lls
D
F
0 .
1 n
M
0 .
0 5 0 .
5 1 0
0 .
0 5 0 .
5 1 0
0
2
4
6
8
F L [ M] F L [ M]
+FICZ
D
F
0 .
1 n
M
0 .
0 5 0 .
5
5 .
0
0 .
0 5 0 .
5
5 .
0
0
2
4
6
8
1 0 IL -2 2
IL
-2
2
[n
g
/m
l]
F L [ M]
+FICZ
F L [ M]
(A) (B)
IL 1 7 A (+ ) , IL -2 2 (- )
%
o
f
liv
e
C
D
4
+
T
ce
lls
D
F
0 .
1 n
M
0 .
0 5 0 .
5 1 0
0 .
0 5 0 .
5 1 0
0
2 0
4 0
6 0
8 0
P Y [ M] P Y [ M]
+FICZ
IL 1 7 A (+ ) , IL -2 2 (+ )
%
o
f
liv
e
C
D
4
+
T
ce
lls
D
F
0 .
1 n
M
0 .
0 5 0 .
5 1 0
0 .
0 5 0 .
5 1 0
0
2
4
6
8
P Y [ M] P Y [ M]
+FICZ
D
F
0 .
1 n
M
0 .
0 5 0 .
5
5 .
0
0 .
0 5 0 .
5
5 .
0
0
2
4
6
8
1 0 IL -2 2
IL
-2
2
[n
g
/m
l]
P Y [ M] P Y [ M]
+FICZ
(C) (D)
D
F
0 .
1 n
M
0 .
0 5 0 .
5
5 .
0
0 .
0 5 0 .
5
5 .
0
0
2
4
6
8
1 0 IL -2 2
IL
-2
2
[n
g
/m
l]
P h e [ M] P h e [ M]
+FICZ
IL 1 7 A (+ ) , IL -2 2 (- )
%
o
f
liv
e
C
D
4
+
T
ce
lls
D
F
0 .
1 n
M
0 .
0 5 0 .
5 1 0
0 .
0 5 0 .
5 1 0
0
2 0
4 0
6 0
8 0
P h e [ M] P h e [ M]
+FICZ
IL 1 7 A (+ ) , IL -2 2 (+ )
%
o
f
liv
e
C
D
4
+
T
ce
lls
D
F
0 .
1 n
M
0 .
0 5 0 .
5 1 0
0 .
0 5 0 .
5 1 0
0
2
4
6
8
P h e [ M] P h e [ M]
+FICZ
(E) (F)
*
******
***
*
*****
*
**
*
******
**
IL -2 2
IL
-2
2
[n
g
/m
l]
D
F
0 .
1 n
M
F L
0 .
5 u
M
P Y
0 .
5 u
M
P h
e
0 .
5 u
M F L P Y P h
e
0
2
4
6
8
1 0
+FICZ
(G)
IL 1 7 A (+ ) , IL -2 2 (+ )
%
o
f
liv
e
C
D
4
+
T
ce
lls
D
F
0 .
1 n
M
F L
0 .
5
M
P h
e
0 .
5
M
P Y
0 .
5
M F L P Y P h
e
0
2
4
6
8
+FICZ
AHR-
KO
Fig. 7. Eﬀects of PAH-type CYP1 inhibitors on FICZ-mediated Th17 cell diﬀerentiation and IL-22 expression. CD4+T cells isolated from isolated from WT or Ahr−/− mice were exposed
to diﬀerent doses of the PAHs ﬂuoranthene (FL; A-B, G), pyrene (PY; C-D, G) or phenanterne (Phe; E-F, G), with or without co-exposure to 0.1 nM FICZ (abbreviated; F). At 96 h exposure
cells were harvested and the fraction of CD4+T cells with intracellular expression of IL17A alone (IL17A(+), IL-22(-)) or with simultaneous expression of IL-22 (IL17A(+), IL-22(+))
were determined using FACS. In parallel, levels of IL-22 excreted to the cell medium were determined using ELISA. All FACS analysis were performed on pooled duplicates from one
experiment while ELISA results are shown as mean ± SD from 2 independent experiments performed in duplicate or triplicate (n= 4–5). Analysis of statistical diﬀerences in IL-22
expression between each exposure compared to the DMSO control was performed using one-way ANOVA followed by Sidaḱs post hoc test to correlate for multiple comparisons. Studentś t
test followed by Holm-Sidak post hoc test was used for statistical analysis of more or less than additive eﬀects. Asterisks indicate statistically signiﬁcant diﬀerences between DMSO control
and respective exposure (∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001). Daggers designate signiﬁcantly more or less than additive eﬀects in co-exposures compared to sum of single
exposures (†p < 0.05).
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of FICZ. Phe showed increased levels of FICZ at 24 h, although only at
the highest dose (Fig. 10D).
4. Discussion
In this study we showed that FICZ-dependent AHR activation and
downstream IL-22 production is strongly enhanced when CYP1 enzyme
function is impaired. Together with our previous report of a critical role
for CYP1enzymes in feedback-regulation of AHR signaling in intestinal
immunity [9], these data suggest that CYP1 enzymes may be essential
for other AHR-regulated functions in the immune system. In this con-
text, reduced catalytic activity of CYP1 enzymes may result in elevated
systemic levels of endogenous AHR ligands such as FICZ, which could
contribute to immune-related adverse eﬀects.
In the present study, the distinct dose- and time dependent eﬀects of
FICZ on AHR signaling in Th17 cells demonstrates two critical aspects
of AHR signaling in Th17 cells. Firstly, Th17 cells are very sensitive to
FICZ-induced AHR activation, supporting previous ﬁndings of high
AHR expression in this cell type [18]. Secondly, Cyp1a1 is inducible
very early in the Th17 diﬀerentiation process which is in line with
previous reports describing Ahr expression as early as 4hrs following
initiation of Th17 diﬀerentiation [37]. Furthermore, the transient
nature of AHR activation by lower concentrations vs. sustained acti-
vation with higher concentrations of FICZ indicates a functional but
limited CYP1 metabolic capacity throughout the diﬀerentiation process,
resulting in antagonistic eﬀects at a high dose. In comparison, dose- and
time-response studies using human keratinocytes (HaCaT) [10] or he-
patoma cells (HepG2) [8] showed steeper transience in response to
FICZ with maximum induction around 2 h and complete termination of
activation at 24 h. Although an antagonistic response by FICZ was ob-
served also in HaCaT cells, this occurred at much higher doses [10],
further pointing to a more limited metabolic capacity in Th17 cells.
A lower capacity to metabolize FICZ would cause not only a pro-
longed AHR activation but also an enhanced Th17 cell diﬀerentiation
and IL-22 production, as was evident when using CYP1-KO CD4+ T
cells. Notably, the diﬀerence in dose-response pattern between CYP1-
KO and WT Th17 diﬀerentiation suggests that CYP1-deﬁcient cells be-
come saturated or even inhibited in their Th17/IL-22 response at FICZ
levels above 10 nM, while WT cells do not. A possible explanation for
these results is AHR antagonism due to cellular accumulation of FICZ
resulting in an “antagonistic internal dose”. However, the mechanism
behind this suppression is not clear and it remains a possibility that
higher doses of FICZ induce an alternative transcriptional program in
CD4+ T cells at the expense of Th17 diﬀerentiation. No changes in
Foxp3 induction were however observed, ruling out competing diﬀer-
entiation into regulatory T cells (Treg) (data not shown).
Altogether, the data generated using the CYP1-KO cells clearly de-
monstrate an essential role of CYP1 metabolic activity in regulation of
IL-22 production and support the notion that altered CYP1 function
may play a role in IL-22 regulated physiological and pathological pro-
cesses. The relatively smaller impact of CYP1-KO on Th17 reiterates our
previous ﬁnding that Th17 cell diﬀerentiation can be enhanced by FICZ
but is not strictly dependent on AHR activation [18].
We and others have previously demonstrated synergistic AHR ac-
tivation and AHR-mediated toxicity at combined exposure to a CYP1-
inhibitor with a metabolizable AHR agonist, and reduced receptor ac-
tivation and toxicity in combination with a poorly metabolized agonist
[8,10,11,14,15,17,24,38–40]. However, the impact of chemical CYP1
inhibition on the Th17/IL-22 response remained unknown. In this
project we clearly demonstrate that chemical CYP1 inhibitors reduce
the cellular clearance of FICZ and strongly potentiate IL-22 production
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Fig. 9. IL-22 production in response to CYP1-inhibitors in a Cyp1-depleted system.
CD4+T cells isolated from WT- or CYP1-KO mice were exposed to FICZ (0.1 nM) or
0.05 μM CYP1 inhibitor (MNF, αNF, FL, PY or Phe) while undergoing Th17 diﬀerentia-
tion. At 72 h exposure cells were harvested and expression of Il22 was determined by
means of qRT-PCR (A-B). Level of expression is normalized to Hprt and given relative to
DMSO control. At 96 h exposure, cell medium was collected and analysed for content of
IL-22 by ELISA (C-D). Gene expression- and ELISA analyses were performed with samples
from separate experiments performed in triplicate and are shown as mean ± SD (n= 3).
Signiﬁcant diﬀerences between DMSO control and respective exposure were determined
using One-way ANOVA followed by Sidak post hoc test to correlate for multiple com-
parisons and are shown by asterisks (∗p < 0.05).
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in an AHR dependent manner in Th17 cells. The results obtained when
exposing CYP1-deﬁcient cells to the separate inhibitors, together with
their impact on cellular clearance of FICZ, support our suggestion of
CYP1-inhibition per se being the mechanism underlying potentiation of
IL-22 expression by these compounds. This was further corroborated by
the lack of potentiation observed after co-exposure to the poorly me-
tabolized ligand TCDD.
The CYP1 inhibitors were selected based on previously demon-
strated eﬀects on CYP1/AHR-feedback regulation (MNF and αNF) or
environmental relevance (FL, Phe and PY). Importantly, our data de-
monstrate that environmentally relevant PAHs, at doses detected in
human blood [31–34], potentiate AHR activation and subsequent IL-22
production by an endogenous receptor ligand. While some PAHs such as
benzo(a)pyrene and 3-methylcholanthrene are known to activate AHR
signaling [41], AHR-potentiation through CYP1 inhibition demon-
strates an additional mechanism through which PAHs and other en-
vironmental pollutants may impair immune homeostasis. Our ﬁndings
postulate a novel mechanism of IL-22 regulation by environmental
factors that could potentially promote the tissue protective functions of
IL-22 in intestinal homeostasis or exacerbate IL-22-driven adverse ef-
fects. Moreover, measurements of maternal blood and cord blood re-
vealed levels of FL, PY and Phe in the same range as included in this
study, suggesting a possible eﬀect of these PAHs on immune system
maturation during early development [34]. It is also important to point
out that in this study cells were exposed to one CYP1 inhibitor at a time,
while humans and wildlife are exposed to complex mixtures that to-
gether may reach higher CYP1-inhibiting potencies.
While all CYP1 inhibitors generated synergistic eﬀects on AHR
signaling and IL-22 expression at co-exposure to FICZ, they diﬀered in
eﬀects when used as single exposures. The antagonistic eﬀect observed
with MNF is in line with previous reports on MNF acting as an AHR
antagonist [10,42] in addition to being a CYP1 inhibitor. In contrast,
αNF has been suggested to act as a weak agonist and partial antagonist,
which could explain the observed induction [43–45] by αNF alone.
However, we recently revealed that AHR activation by αNF is depen-
dent on receptor agonists in the cell culture medium [10] and that in
vitro diﬀerentiation of Th17 cells are highly inﬂuenced by same
medium ligands [46], conﬁrming that the observed eﬀects by αNF most
likely is not due to AHR agonism per se. Thus, diﬀerences in dose- and
time-response observed with MNF and αNF alone and in co-exposure to
FICZ are likely due to their innate diﬀerences in potency to inhibit the
function of CYP1 enzymes [10,26,47] and to antagonize AHR signaling
[48,49]. The antagonistic switch observed with αNF in CYP1-KO cells
may partly be explained by altered metabolism of αNF itself since CYP1
enzymes has shown to metabolize αNF [50–52] into even stronger
CYP1 inhibitors [53]. The discrepancy between eﬀects of single ex-
posures of PAHs on Il22 gene expression and IL-22 excretion is not fully
clear but is likely due to the diﬀerence in length of exposure (72 h for
gene expression vs. 96 h for FACS and ELISA analysis) and the cumu-
lative levels of IL-22 measured in the cell medium compared to the
time-point speciﬁc measurement of gene expression.
Collectively, our data demonstrate that chemical CYP1-inhibition
potentiates IL-22 production and this ﬁnding could have important
implication for intestinal homeostasis. The intestinal immune system is
exposed to a plethora of CYP1 inhibitory agents derived from en-
vironmental pollution [10] that may induce prolonged AHR pathway
activation and IL-22 production. The receptor for IL-22 is restricted to
non-hematopoietic cells such as intestinal epithelial cells (IEC) and
dysregulated IL-22 signaling is associated with the development of
colorectal cancer (CRC) through increased proliferation and survival of
intestinal stem cells [19]. The use of CYP1 enzymes as therapeutic
target in cancer prevention has been discussed extensively based on the
overexpression of Cyp1 in diﬀerent tumors and the role of CYP1 in
metabolic activation of pro-carcinogens [54–57]. However, CYP1-KO
mice are reported to have increased DNA adduct levels following ex-
posure to the PAH benzo[a]pyrene (BaP) [58] and CYP1A1 induction in
the GI tract is absolutely required for detoxiﬁcation of oral BaP [59],
suggesting that functional CYP1 enzyme can also act as a tumor sup-
pressor. Thus, CYP1 inhibition and subsequent potentiation of IL-22
production may represent an additional mechanism by which by en-
vironmental pollutants promote cancerogenesis.
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Fig. 10. Impact of CYP1 inhibitors on cellular clearance of
FICZ. Eﬀects of low and high concentrations of αNF or MNF
(A-B) and the PAHs ﬂuoranthene (FL), pyrene (PY) or phe-
nanthrene (Phe) (C-D) on FICZ metabolism was determined
by measuring cellular levels of FICZ (pmol/mg protein)
upon co-exposures to respective CYP1 inhibitor. Results are
shown as mean ± SD from one experiment performed in
triplicate (n= 3). Diﬀerences in levels of FICZ in co-ex-
posures compared to exposure to FICZ alone were de-
termined using Two-way ANOVA followed by Dunnettś post
hoc test to correlate for multiple comparisons. Statistically
signiﬁcant diﬀerences are shown by asterisks (∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.001).
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